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Abstract 
Objectives: Cardiovascular disease is rare in premenopausal women, but increases after the menopause when hormone replacement 
therapy reduces coronary events. Vascular smooth muscle cell @MC) proliferation and migration occur in atherosclerosis, restenosis and 
venous graft disease. We studied the effects of 17@estradiol n SMC proliferation and migration. Methods: SMC were cultured from 
saphenous veins of postmenopausal women and age-matched men. Cell growth was determined by ‘H-thymidine incorporation and cell 
counting. Migration of SMC was assessed in 4-well chambers. SMC were seeded in one comer and PDGF-BB in filter paper glued onto 
the opposite wall. Results: PDGF-BB (5 rig/ml for 24 h) similarly stimulated ‘H-thymidine incorporation in female (5 11 f 57%; n = 8) 
and male (528 f 62%; R- 12) SMC. This was reduced by 17pestradiol (1O-s-1O-6 M, female 313 f 52%; male 337 f 54%; 
P < 0.05). PDGF-BB increased the number of SMC (P < 0.0001 at 10 days) obtained from females (153 f 3%; n - 5) and males 
(150 f 4%; n = 51, which was inhibited by 17&estradiol (10m6 M, female 134 * 7%; male 128 f 5%; P < 0.05). Similar results were 
obtained with basic fibroblast growth factor. In contrast o 17P-estradiol, another steroid (dexamethasone) had no effects on 3H-thymidine 
incorporation in these cells stimulated with PDGF-BB. PDGF-BB (0.01-l ng> stimulated SMC migration (P < 0.05) which was inhibited 
by 17p-estradiol (10-‘“-10-6 M; n - 5; P < 0.005). Conclusion: 17@-Estradiol inhibits growth-factor-induced SMC proliferation and 
migration regardless of gender. These effects of 17@estradiol may contribute to its cardiovascular protective properties in post- 
menopausal women during replacement therapy. 
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1. Introduction 
Coronary artery disease is the leading cause of death in 
industrialized countries. Percutaneous transluminal coro- 
nary angioplasty (F’TCA) and bypass surgery are well- 
established methods of treating these patients [1,2]. How- 
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ever, both procedures do not prevent progression of the 
disease. Furthermore, PICA is associated with restenosis 
and bypass surgery with graft disease, particularly venous 
graft disease [1,2]. Cell proliferation and migration are 
believed to be critical for accumulation of smooth muscle 
cells @MC) in the intima, and this may be important for 
vascular luminal narrowing [3,4]. Platelet-derived growth 
factor (PDGF) and basic fibroblast growth factor (bFGF) 
released from platelets and activated vascular cells are 
considered to be important in triggering SMC proliferation 
and migration [3,4]. 
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The incidence of coronary artery disease in pre- 
menopausal women is lower than in men and increases 
after the menopause [5-71. Estrogen replacement therapy 
in postmenopausal women markedly reduces cardio- 
vascular events [5,8,9]. Hence, female sex hormones and 
17@estradiol in particular may protect women against 
vascular disease [5]. However, the cardiovascular protec- 
tive effects of estrogens remain unclear, althought it has 
been documented that they inhibit vasoconstriction i  an 
endothelium-dependent as well as endothelium-indepen- 
dent manner [lo-141. Furthermore, estrogens favorably 
change the lipid metabolic profile [5,15]. More recent 
studies on the rat aorta and human coronary artery circula- 
tion demonstrated gender differences in endothelial func- 
tion modulating vascular tone [ 16,171. This study was 
designed to investigate whether a gender difference con- 
cerning the effects of 17B-estradiol n SMC proliferation 
and migration exists in cells obtained from post- 
menopausal women and age-matched men. 
2. Methods 
2.1. Materials 
Bovine serum albumin, 17@-estradiol, dexamethasone, 
monoclonal antibody against o-smooth muscle actin and 
cytosine+D-arabinofuranoside w re obtained from Sigma 
(Buchs, Switzerland), recombinant platelet-derived growth 
factor-BB, basic fibroblast growth factor, fibronectin, 
agarose and all tissue culture materials were obtained from 
Gibco (Basel, Switzerland). 3H-Methylthymidine was from 
Amersham @rich, Switzerland), trichloroacetic acid from 
Fluka (Buchs, Switzerland), and blotting paper (GBOO4) 
from Schleicher and Schuell (Feldbach, Switzerland). 
2.2. Isolation and cultivation of cells 
Vascular SMC were isolated from saphenous veins of 8 
postmenopausal women without estrogen replacement ther- 
apy (mean age 65 years, range 57-72) and 12 age-matched 
men (mean age 62 years, range 55-71; n.s.> undergoing 
coronary bypass surgery by explant echnique as described 
previously [ 181. Vascular SMC were cultured in phenol 
red-free Dulbecco’s Modified Eagle Medium (DMEM) 
containing 20% fetal calf serum (FCS) supplemented with 
2 mM L-glutamine and 10 mM HEPES buffer solution, 
100 U/ml penicillin and 100 kg/ml streptomycin in a 
humidified atmosphere (37°C; 95% sir/5% CO,). In cer- 
tain experiments, cells were grown in culture medium 
containing phenol red. Culture medium was replaced every 
3 days. Cells were passaged by trypsinization (0.05% 
trypsin-EDTA). Experiments were performed between pas- 
sages 3 and 6. SMC were characterized by indirect im- 
munofluorescence staining using specific anti-smooth- 
muscle a-actin antibodies [ 18,191. 
2.3. Assay of cell mitogenicity 
Cells were seeded on 12-well plates (density: 104/ml 
for 24 h to allow attachment). Culture media were then 
replaced with phenol-red-free, serum-free DMEM medium 
containing all ingredients as described above and 0.2% 
bovine serum albumin (BSA) instead of FCS. Cells in 
serum-free DMEM medium were incubated with or with- 
out 17B-estradiol (1O-8-1O-5 M) for 48 h before stimula- 
tion with PDGF-BB (5 rig/ml) or bFGF (5 rig/ml). 
3H-Thymidine incorporation was assayed as described pre- 
viously [18,19]. Incorporated radioactivity was measured 
with a B-counter (ICN, Intertechnique, France). In parallel 
experiments, cell number was counted. Quiescent SMC 
were treated with or without 17B-estradiol (10e6 M) or 
vehicle (2-hydroxypropyl+-cyclodextrin) for48 h and then 
stimulated with PDGF-BB (5 rig/ml) every 2 days with or 
without 17B-estradiol (10m6 M). Cell number was counted 
at day 10 (Coulter counter; England). 
2.4. Migration of smooth muscle cells 
Migmtion assays were performed in 4-well chambers 
coated with fibronectin (5 pg/ml). VSMC 3 X 10’ in 100 
pl DMEM without phenol red supplemented with 20% 
FCS were seeded in one comer of the chambers and 
incubated overnight o allow for cell attachment. The cells 
were then washed 3 times with serum-free medium (con- 
taining 0.2% BSA) and a start line was drawn along the 
edge of the attached cells. On the opposite side of the 
chamber, an g-mm’ filter paper preincubated in 0.1% 
agarose containing PDGF-BB (O.Ol- 1 ng/fiher) was glued 
onto the opposite wall of the chambers by using preheated 
(50°C) 0.5% agarose. 800 p,l serum-free medium supple- 
mented with 50 mM cytosine-P-D-arabinofuranoside were 
added to each chamber. The cells were incubated for 
another 48 h and at the end of the migration assay the cells 
were then washed with PBS, fixed with 4% paraformal- 
dehyde, and stained with hematoxylin. The migration of 
VSMC was assessed by blinded counting of the number of 
cells observed across the start line using light microscopy. 
To investigate possible inhibitory effects of 17B-estradiol 
on PDGF-BB-induced VSMC migration, the cells were 
pretreated with 17B-estradiol for 24 h. The migration 
assays were then performed with PDGF-BB at the optimal 
stimulatory dose (1 rig/filter). 
2.5. Statistical analysis 
All experiments were performed in triplicate. Data are 
presented as percent of control and given as means f s.e.m. 
One-way factorial analysis of variance @NOVA) was 
used for statistical analysis. n equals number of patients. A 
two-tailed P-value smaller than 0.05 was considered sig- 
nificant .
982 D. Dai-Do et al. / Cardiovascular Research 32 (1996) 980-985 
3. Results 
3.1. Efsects of estrogen on cell proliferation 
PDGF-BB (0.01 to 10 rig/ml) concentration-depen- 
dently stimulated 3H-thymidine incorporation which 
reached a maximum at 5 rig/ml. PDGF-BB (5 rig/ml) 
increased 3H-thymidine incorporation into vascular smooth 
muscle cells obtained from postmenopausal women (511 
rf: 57% above control; Fig. 1 left; n = 8; P < 0.0001 
versus control) and by 528 f 62% in cells obtained from 
age-matched men (Fig. 1 right; n = 12; P < 0.0001 versus 
control). 17B-Estradiol (1O-8-1O-6 M) reduced 3H- 
thymidine incorporation into vascular smooth muscle cells 
from postmenopausal women to 313 f 52% (n = 8; P < 
0.05 versus PDGF-BB alone) and to a similar degree also 
in those obtained from men (337 f 54%; n = 12; P < 0.05 
versus PDGF-BB alone). The vehicle, 2-hydroxypropyl- 
B-cyclodextrin, had no effects on PDGF-BB-stimulated 
cell proliferation. If vascular smooth muscle cells were 
cultured in medium containing phenol red, no inhibitory 
effect of 17B-estradiol on PDGF-BB-induced 3H-thymi- 
dine incorporation was observed. After 10 days of stimula- 
tion with PDGF-BB (5 rig/ml), the number of vascular 
smooth muscle cells obtained from women (Fig. 2, left; 
153 f 3%, n = 5; P < 0.0001 versus control) as well as 
from men was increased (Fig. 2, right; 150 f 4%, n = 5; 
P < 0.0001 versus control). 17B-Estradiol (10e6 Ml re- 
duced cell numbers in female cells (134 + 7%, n = 5; 
P < 0.05 versus PDGF-BB alone) as well as in male cells 
(128 + 5%; n = 5; P < 0.05 versus PDGF-BB alone), 
while the hormone alone did not change the cell number 
(Fig. 2; n.s. versus control). 
In contrast to 17B-estradiol, dexamethasone (10-9- 10F6 
M), also a steroid, had no effects on 3H-thymidine incor- 
Female Male 
(n=X) (n=IZI 
600 le 
PDGF-BB (5ng/ml) - + + + + - + + + + 
l’lb-estradiol CM) - - 10-n 10-7 IO-6 _ _ 10-x lo-7 IO-6 
Fig. 1. Effects of 17B-estradiol n DNA synthesis timulated by PDGF-BB 
in vascular smooth muscle cells of female (left panel) and male patients 
(right panel). PDGF-BB stimulated 3H-thymiclme incorporation after 24 
h; 17B-estradiol reduced this effect. Data are shown as mean f s.e.m. (n 
= number of patients). * P < 0.0001 vs. control; tf’ < 0.05 vs. PDGF- 
BB alone. 
2 175 
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.- 1 III=51 (IdI 
PDGF-BBCSng/ml) - + + - - + + - 
l’lfkstradiol (lo-GM) _ - + + - - + + 
Fig. 2. Effects of 17B-estradiol n increase in cell numbers timulated by 
PDGF-BB in human vascular smooth muscle cells of female (left panel) 
and male patients (right panel). PDGF-BB increased cell number after 10 
days of stimulation, which was reduced by 17B-estradiol (10e6 M), while 
the hormone alone had no effect. Data are shown as mean f s.e.m. (n = 
number of patients). * P < O.ooOl vs. control; tP < 0.05 vs. PDGF-BB 
alone. 
poration into cells stimulated with PDGF-BB (5 rig/ml; 
Fig. 3; n = 15, 8 males and 7 females). 
Similar results to those with PDGF were obtained in 
cells stimulated with bFGF, where 17B-estradiol also in- 
hibited the effects of the growth factor on 3H-thymidine 
incorporation (n = 9, 4 females and 5 males; P < 0.05, 
Fig. 4 right). Heparin (0.1-100 pg/ml), however, exhib- 
ited a more pronounced inhibitory effect on 3H-thymidine 
incorporation stimulated with bFGF (5 rig/ml) in the 
smooth muscle cells (n = 5, 3 females and 2 males; P < 
0.05, Fig. 4 left). 
3.2. Effects of estrogen on cell migration 
PDGF-BB (O.Ol- 10 rig/filter) induced a dose-depen- 
dent increase in the migration of human saphenous vein 
PDGF-BB (Sng/ml) - + + + + + 
Deramethasone(M) . . IO-9 IO-8 lo-7 lo-6 
Fig. 3. Effects of dexamethasone on DNA synthesis stimulated by 
PDGF-BB in vascular smooth muscle cells. Preincubation of the cells 
with the steroid dexamethasone for 48 h had no effects on PDGF-BB 
stimulated 3H-thymidine incorporation after 24 h. Data are shown as 
mean f s.e.m. (n = number of patients). l P < 0.001 vs. control. 
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bFGF (5ng/ml) - 
Heparin (@ml) - 
* 
350, n=9 
+ + + + + bFGF (Sng/ml) - + + + + 
w 0.1 1 10 loo 17P-estradiol (M) - - 10-7 10-6 IO-5 
Fig. 4. Comparision of the effects of heparin (left panel) and 17/3-estradiol (right panel) on DNA synthesis timulated by bFCiF in human vascular smooth 
muscle cells. Note that bFGF potently stimulated “H-thymidine incorporation which was abolished by heparin (left panel; n = 5, P < 00.5) and reduced by 
Ill@estradiol (right panel; n = 9; P < 0.05). l P < 0.05 vs. control; TP < 0.05 vs. PDGF-BB alone. 
smooth muscle cells (Fig. 5A). The maximal effect oc- 
curred at 1 ng of PDGF-BB, where migration was stimu- 
lated more than 5-fold over control (P < 0.05; n = 4, 3 
males and 1 female). 
Prior incubation of smooth muscle cells with 17p- 
estradiol (lo- lo- 1 O- 6 M) concentration-dependently in- 
A 
160 1 n=a 
hibited PDGF-sinduced migration (Fig. 5B). The number 
of migrated smooth muscle cells was reduced at 10e9 M 
of 17B-estradiol (P < 0.05) and was maximal (P < 0.005; 
n = 5, 3 males and 2 females) at 10S6 M as compared 
with PDGF-BB alone. 
4. Discussion 
Control 0.01 0.1 1 10 
PDGF-BB @/filter) 
120- 
L 
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o- 
C0ntr0l ‘- PDGF - BB (Ing/filter) -s-L 
17f3-&radio1 (M) 0 lo-10 lo-9 lo-8 10-7 10-e 
Fig. 5. Stimulation of migration of human sapheneous vein SMC in 
culture by PDGF-BB. PDGF-BB (0.01-10 rig/filter) induced a dose-de- 
pendent migration of the cells (top panel; n = 4, l P < 0.05 vs. control). 
in cells pretreated with 17e-estradiol ( O-‘“-lO-” M) these effects of 
PDGF-BB were concentration-dependently inhibited by Ills-estradiol 
(lower panel; n = 5, tP < 0.05 vs. control; l ’ l l P < 0.05 to 0.005 vs. 
PDGF-BB alone). 
This study demonstrates that 17E-estradiol inhibits pro- 
liferation and migration of human vascular smooth muscle 
cells of saphenous veins stimulated by mitogens such as 
platelet-derived growth factor and basic fibroblast growth 
factor. Most interestingly, these antiproliferative and an- 
timigratory effects of 17B-estradiol occurred in vascular 
smooth muscle cells obtained from postmenopausal women 
as well as from age-matched men with coronary artery 
disease. 
Protective effects of estrogens against cardiovascular 
disease in postmenopausal women are well documented 
[5]. Putative mechanisms may involve endothelium-depen- 
dent and -independent vasodilation [lo-141 and an im- 
proved lipid profile [5,15]. Furthermore, estrogen stimu- 
lates endothelial nitric oxide synthase activity in vivo [20], 
and may inhibit smooth muscle cell proliferation via en- 
dothelium-derived nitric oxide [21]. Proliferation and mi- 
gration of vascular smooth muscle cells are believed to 
contribute significantly to intimal thickening in athero- 
sclerosis, restenosis and venous bypass graft disease [2,3]. 
Experiments with cultured vascular smooth muscle cells 
obtained from rats and pigs, however, revealed inconsis- 
tent antiproliferative ffects of 17P-estradiol [22,23], sug- 
gesting important species differences or vessel differences. 
This study provides the first evidence that 17@estradiol 
inhibits smooth muscle cell proliferation in post- 
menopausal women and also in men with coronary artery 
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disease. In unstimulated cultured human vascular smooth 
muscle cells, 17P-estradiol alone exerted no significant 
effects in line with the observation by Calcagno et al. who 
did not find antiproliferative ffects of estrogen on ‘H- 
thymidine uptake in human saphenous vein organ culture 
[24] when the vessels were not stimulated with growth 
factors. However, in cells stimulated with either platelet- 
derived growth factor or basic fibroblast growth factor, 
17@estradiol inhibited 3H-thymidine uptake of these cells, 
although the effect was much weaker than heparin. In 
contrast to 17l3-estradio1, the steroid, dexamethasone, 
which has been shown to exert antiproliferative ffects in 
diseased (atherosclerotic) smooth muscle cells [25] and 
inhibits intimal thickening in rat carotid artery after bal- 
loon injury [26], had no effects on DNA synthesis in these 
venous smooth muscle cells. The different observations 
between the present study and those previous studies may 
be due to the different cell types and species used. In 
addition, 17l3-estradiol reduced the increase in cell num- 
bers evoked by platelet-derived growth factor. These re- 
sults, therefore, indicate that 17l3-estradiol specifically in- 
terferes with the effects of growth factors in vascular 
smooth muscle cells. The fact that the antiproliferative 
effects of 17P-estradiol were comparable in cells obtained 
from postmenopausal women to those from age-matched 
men indicates that vascular smooth muscle can respond to 
17P-estradiol regardless of gender, at least at this age 
stage. Whether smooth muscle cells from premenopausal 
women have similar behavior remains unclear. The con- 
centrations used in the present study to inhibit cell prolifer- 
ation are beyond the physiological range in vivo, but are 
the same as those used in other studies which demon- 
strated acute effects of the hormone on the blood vessel 
wall [17,27]. It is conceivable, however, that with pro- 
longed exposure to estrogens similar effects on blood 
vessel wall may occur even at physiological concentra- 
tions. 
In addition to proliferation, migration of vascular smooth 
muscle cells contributes ignificantly to vascular structural 
changes occurring in atherosclerosis, restenosis and venous 
graft disease [3,4,28-301. In this study, 17@estradiol was 
most effective in inhibiting migration of human vascular 
smooth muscle cells induced by platelet-derived growth 
factor. It has been discussed that migration of smooth 
muscle cells from the media into the intima accounts in 
large part for the accumulation of this cell type in athero- 
sclerotic as well as intimal hyperplasia occurring after 
balloon injury [4,28-301. The evolving concept of vascular 
remodeling [4] may also involve considerably the migra- 
tory responses of smooth muscle cells of the media. 
The cellular mechanisms of the antiproliferative and 
antimigratory effects of 17@estradiol may involve several 
pathways. The classical pathway utilized by 17p-estradiol 
and related steroids involves activation of the estrogen 
receptor [31]. This receptor is located intracellularly and is 
translocated into the nucleus after binding of its specific 
ligand [31]. RT-PCR demonstrated mRNA expression of 
estrogen receptors in vascular smooth muscle cells of both 
female and male patients (data not shown). This is in 
agreement with previous studies and further for the first 
time demonstrates that the receptor is expressed regardless 
of the gender of cells [32]. Compared to MCF-7 cells, a 
mammary carcinoma cell line [32], and human umbilical 
vein endothelial cells, the expression levels were lower. 
Also, Northern blot analysis did not reveal a reliable signal 
in vascular smooth muscle cells (unpublished observation) 
as observed by others as well 1321, suggesting that the 
degree of receptor expression is lower than in tissue 
obtained from the mammary gland or sexual organs or 
endothelial cells. Phenol red interferes with estrogen recep- 
tors [33] and in this study prevented the inhibitory effects 
of 17P-estradiol on proliferation induced by platelet-de- 
rived growth factor. However, it is still unclear whether 
the estrogen receptor mediates these effects of the hor- 
mone in these particular cells, since estrogens also bind to 
membrane-associated binding sites [34] and three splicing 
variants of estrogen receptors in addition to the wild type 
of the receptor have been identified in rat vascular smooth 
muscle cells by a recent study [35]. 
Antiproliferative and antimigratory effects of estrogen 
in vascular smooth muscle cells may contribute to a lower 
incidence of cardiovascular disease in premenopausal 
women than in age-matched men [9]. In addition, these 
effects may-together with the effects of estrogens on risk 
factors [36] and endothelial cells [37]-account for the 
reduction of cardiovascular events seen with hormone 
replacement therapy in postmenopausal women [5,9]. In- 
terestingly, in premenopausal women with atherosclerotic 
coronary artery disease, a decreased estrogen receptor 
expression in the vasculature has been demonstrated [38]. 
This strongly suggests aprotective role of estrogens against 
coronary artery disease in women and a role of estrogen 
receptor expression in the development of the disease. Our 
study further raises the posssibility that males also would 
benefit from stimulation of the estrogen receptors in vascu- 
lar smooth muscle; however, the side-effects of this ap- 
poach in other organs such as the testes and breast issue 
render the use of this hormone unacceptable for primary or 
secondary prevention in the male. It is conceivable, how- 
ever, that local delivery of the hormone (e.g., after percuta- 
neous transluminal angioplasty to 
may be used also in male patients. 
prevent rester&is [ 1 I) 
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